文献速递类风湿关节炎

血清钙卫蛋白(S100A8/A9)对类风湿关节炎患者开始或减量抗TNF治疗后临床缓解的预测价值

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2018-04-09

研究基于BIO-TOP和DRESS两项纵向研究,评估血清钙卫蛋白预测类风湿关节炎患者开始或减量抗TNF治疗后临床缓解的价值。BIO-TOP中应答者钙卫蛋白高于无应答者,预测EULAR良好应答的AUC为0.61;加入钙卫蛋白的预测模型与基线模型性能相似。DRESS中减量后三组钙卫蛋白水平相似,对减量后临床缓解无预测价值。

要点

  • 开始抗TNF治疗前钙卫蛋白较高与EULAR良好应答相关,但预测能力有限。
  • 钙卫蛋白加入临床预测模型未增加预测价值。
  • 低疾病活动度患者减量抗TNF治疗时,钙卫蛋白无预测价值。

核心结论

  • 血清钙卫蛋白对开始抗TNF治疗后的临床缓解有一定预测价值,但对其他临床因素无附加价值。
  • 在低疾病活动度患者中,血清钙卫蛋白对减量抗TNF治疗后的临床缓解无预测价值。

研究设计与样本

  • 基于两项类风湿关节炎纵向研究:BIO-TOP研究和DRESS研究。
  • 基线(开始或减量阿达木单抗或依那西普)时用ELISA测定血清钙卫蛋白水平。
  • BIO-TOP研究在6个月时用EULAR应答标准评估治疗效果。
  • DRESS研究在18个月时将患者分类为成功减量、停药或无法减量。
  • 用ROC曲线下面积(AUC)评估钙卫蛋白的预测价值,并建立逻辑预测模型评估其附加价值。

主要发现

  • BIO-TOP研究中,应答者(n=50)钙卫蛋白水平为985 ng/mL(p25-p75:558-1417),高于无应答者(n=75)的645 ng/mL(p25-p75:415-973),p=0.04。
  • 预测EULAR良好应答的AUC为0.61(95% CI 0.50至0.71)。
  • 含钙卫蛋白的预测模型AUC为0.77(95% CI 0.68至0.85),与基线模型AUC 0.74(95% CI 0.65至0.82)性能相似,p=0.29。
  • DRESS研究中,三组(n=47;n=19;n=36)钙卫蛋白水平相似,钙卫蛋白对减量后临床缓解无预测价值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Calprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid arthritis (RA). The aim of this study was to investigate the predictive value of serum calprotectin for clinical response after starting and tapering anti-tumour necrosis factor treatment in RA. METHODS: Serum samples and clinical outcomes were derived from two longitudinal RA studies.At baseline (starting or tapering of adalimumab or etanercept), calprotectin levels were determined by ELISA. In the Biologic Individual Optimised Treatment Outcome Prediction (BIO-TOP) study, treatment effect was assessed after 6 months using the European League Against Rheumatism (EULAR) response criteria. In the Dose Reduction Strategies of Subcutaneous TNF Inhibitors (DRESS) study, patients were classified at 18 months as being successfully dose reduced, discontinued or not able to reduce the dose. Area under the receiver operating characteristic curves (AUC) were generated to evaluate the predictive value of calprotectin and logistic prediction models were created to assess its added value. RESULTS: In the BIO-TOP study, calprotectin levels were higher in responders (n=50: 985 ng/mL (p25-p75: 558-1417)) compared with non-responders (n=75: 645 ng/mL (p25-p75: 415-973), p=0.04).AUC for predicting EULAR good response was 0.61 (95% CI 0.50 to 0.71). The prediction model with calprotectin (AUC 0.77, 95% CI 0.68 to 0.85) performed similarly to the baseline model (AUC 0.74, 95% CI 0.65 to 0.82, p=0.29). In the DRESS study, calprotectin levels were similar between the three groups (n=47; n=19; n=36) and calprotectin was not predictive for clinical response after tapering. CONCLUSIONS: Serum calprotectin has some predictive value for clinical response after starting anti-TNF treatment, although it has no added value to other clinical factors. In patients with low disease activity, serum calprotectin is not predictive for clinical response after tapering anti-TNF treatment. TRIAL REGISTRATION NUMBER: NTR4647 (BIO-TOP study) and NTR3216 (DRESS study); Pre-results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tweehuysen L, den Broeder N, van Herwaarden N, et al. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open. 2018. PMID: 29657832. doi:10.1136/rmdopen-2018-000654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。